Nurix pushes its degrader forward
The company will start its confirmatory bexobrutideg study in June.
BeOne starts another front-line sonrotoclax fight
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
